Legal & General Group PLC Immunovant, Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 59,092 shares of IMVT stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,092
Previous 59,092 -0.0%
Holding current value
$1.63 Million
Previous $1.63 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$27.51 - $27.51 $38,789 - $38,789
1,410 Added 2.44%
59,092 $1.63 Million
Q2 2024

Aug 14, 2024
BUY
$25.1 - $31.61 $110,841 - $139,589
4,416 Added 8.29%
57,682 $1.52 Million
Q1 2024

May 14, 2024
SELL
$30.27 - $43.79 $6,719 - $9,721
-222 Reduced 0.42%
53,266 $1.72 Million
Q4 2023

Feb 15, 2024
SELL
$31.31 - $44.19 $182,224 - $257,185
-5,820 Reduced 9.81%
53,488 $2.25 Million
Q3 2023

Nov 14, 2023
BUY
$18.55 - $39.96 $158,231 - $340,858
8,530 Added 16.8%
59,308 $2.28 Million
Q2 2023

Aug 14, 2023
BUY
$14.2 - $23.75 $507,110 - $848,160
35,712 Added 237.04%
50,778 $963,000
Q1 2023

May 15, 2023
BUY
$15.27 - $19.72 $13,239 - $17,097
867 Added 6.11%
15,066 $233,000
Q3 2022

Nov 14, 2022
SELL
$3.93 - $6.37 $58,399 - $94,658
-14,860 Reduced 51.14%
14,199 $80,000
Q2 2022

Aug 22, 2022
SELL
$3.38 - $5.65 $2,619 - $4,378
-775 Reduced 2.6%
29,059 $113,000
Q1 2022

May 16, 2022
BUY
$5.06 - $8.77 $713 - $1,236
141 Added 0.47%
29,834 $164,000
Q4 2021

Feb 14, 2022
BUY
$7.33 - $9.32 $11,999 - $15,256
1,637 Added 5.83%
29,693 $253,000
Q3 2021

Nov 15, 2021
BUY
$7.01 - $11.37 $49,567 - $80,397
7,071 Added 33.7%
28,056 $244,000
Q2 2021

Aug 12, 2021
SELL
$9.4 - $16.85 $8,121 - $14,558
-864 Reduced 3.95%
20,985 $222,000
Q1 2021

May 17, 2021
BUY
$13.08 - $49.6 $213,047 - $807,884
16,288 Added 292.9%
21,849 $351,000
Q4 2020

Feb 12, 2021
SELL
$36.36 - $52.71 $9,889 - $14,337
-272 Reduced 4.66%
5,561 $258,000
Q3 2020

Nov 13, 2020
BUY
$22.61 - $38.9 $38,097 - $65,546
1,685 Added 40.62%
5,833 $206,000
Q2 2020

Aug 14, 2020
BUY
$13.87 - $28.44 $57,532 - $117,969
4,148 New
4,148 $101,000

Others Institutions Holding IMVT

# of Institutions
211
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email